HIV Infections Clinical Trial
— Couples CoOpOfficial title:
Venue-Based Recruitment and HIV Prevention for Alcohol and Other Drug (AOD) Using Couples in South Africa
| Verified date | October 2015 |
| Source | RTI International |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Federal Government |
| Study type | Interventional |
Couples who use alcohol and other drugs (AOD) in South Africa are at high risk for engaging
in risky sex behavior within their relationships and with other sexual partners. In
addition, high levels of gender-based violence (GBV) in the Cape Town area intersect with
AOD abuse and sex behavior. All of these interconnections raise concern for the importance
of HIV prevention strategies within or surrounding drinking venues, where many of these
behaviors occur.
The specific aims of this study are as follows:
Aim 1. To characterize the types of drinking venues (e.g., licensure status, size, plumbing,
type of alcohol provided), their immediate context (e.g., observed availability and use of
other drugs, observable violence and sexual activity), and surrounding neighborhood
characteristics (e.g., quality of streets, building structures, and availability of
electricity and plumbing) in the sampled neighborhood blocks in several large Black/African
and Coloured communities in Cape Town, South Africa.
Aim 2. To refine through qualitative methods the proposed interventions in relation to
skills-building to address gender-role expectations, sexual partnering, gender and power,
violence, and environments where drinking and sexual risk behaviors occur.
Aim 3. To conduct a randomized group trial to compare the relative efficacy of a
comprehensive intervention (Condition 3: Enhanced Couples) to the gender-focused
intervention (Condition 2: Gender) and to (Condition 1: Men's Control and Women's CoOp) on
reducing alcohol and other drug (AOD) use, sexual risk behavior, and gender-based violence
at 6 month follow-ups. Aim 4. To assess the mechanisms through which the intervention
effects may occur (e.g., mediators involving self-efficacy and condom mastery, negotiation,
and communication skills) and to identify groups for whom the interventions have the
greatest effect (e.g., partner characteristics such as race, gender, and age and
neighborhood factors such as poverty) on study outcomes of AOD use, sexual risk, and
gender-based violence.
| Status | Completed |
| Enrollment | 600 |
| Est. completion date | September 2012 |
| Est. primary completion date | September 2012 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Men Inclusion: - Male - 18-35 - Identify as Black or Coloured - Live in one of the target communities— Khayelitsha, Mitchell's Plain and Delft - Have the same main heterosexual sex partner for at least one year, plan to stay with this partner for at least one year and do not plan to get this partner pregnant within the next year - Report unprotected sex at least once in the past 90 days with main partner - Have used alcohol in a tavern or shebeen in the past 90 days - Spend time in a tavern or shebeen at least weekly Exclusion - Have been a part of previous Couples' Health CoOp group study activities - Are currently enrolled in an HIV research study Women Inclusion: - Female - 18 or older - Have the same main heterosexual sex partner for at least one year and plan to stay together with this partner for at least one year and do not plan to get pregnant within the next year with this partner - Report unprotected sex at least once in the past 90 days with main partner Exclusion: - Have been a part of previous Couples' Health CoOp group study activities - Are currently enrolled in an HIV research study - Have been a part of the Cape Town Pilot Study or the Western Cape Women's Health CoOp |
Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
| Country | Name | City | State |
|---|---|---|---|
| South Africa | Medical Research Council | Cape Town |
| Lead Sponsor | Collaborator |
|---|---|
| RTI International | Medical Research Council, South Africa, National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
South Africa,
Browne FA, Wechsberg WM. The intersecting risks of substance use and HIV risk among substance-using South African men and women. Curr Opin Psychiatry. 2010 May;23(3):205-9. doi: 10.1097/YCO.0b013e32833864eb. Review. — View Citation
Doherty IA, Myers B, Zule WA, Minnis AM, Kline TL, Parry CD, El-Bassel N, Wechsberg WM. Seek, Test and Disclose: knowledge of HIV testing and serostatus among high-risk couples in a South African township. Sex Transm Infect. 2016 Feb;92(1):5-11. doi: 10.1136/sextrans-2014-051882. Epub 2015 Jul 14. — View Citation
El-Bassel, N., & Wechsberg, W.M. Couple-based behavioral HIV intervention: Placing HIV risk-reduction responsibility on the female and male dyad. Couple and Family Psychology 1(2) 94-105, 2012. doi:10.1037/a0028890
Minnis AM, Doherty IA, Kline TL, Zule WA, Myers B, Carney T, Wechsberg WM. Relationship power, communication, and violence among couples: results of a cluster-randomized HIV prevention study in a South African township. Int J Womens Health. 2015 May 11;7:517-25. doi: 10.2147/IJWH.S77398. eCollection 2015. — View Citation
Wechsberg WM, Doherty IA, Myers B, Morgan-Lopez AA, Emanuel A, Carney T, Kline TL, Zule WA. Contextualizing gender differences and methamphetamine use with HIV prevalence within a South African community. Int J Drug Policy. 2014 May;25(3):583-90. doi: 10.1016/j.drugpo.2013.10.016. Epub 2013 Nov 9. — View Citation
Wechsberg WM, Myers B, Reed E, Carney T, Emanuel AN, Browne FA. Substance use, gender inequity, violence and sexual risk among couples in Cape Town. Cult Health Sex. 2013;15(10):1221-36. doi: 10.1080/13691058.2013.815366. Epub 2013 Aug 8. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Reduced alcohol use | 6 month follow up | No | |
| Secondary | reduced gender-based violence | 6 month follow up | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |